论文部分内容阅读
AIM:To determine the efficacy of an interferon alphaand ribavirin combination treatment for Japanese pa-tients infected with hepatitis C virus (HCV) of genotype 2,a multi-center study was retrospectively analyzed.METHODS:In total,173 patients with HCV genotype 2started to receive interferon-alpha subcutaneously thricea week and 600-800 mg of ribavirin daily for 24 wk.RESULTS:The overall sustained virological response(SVR),defined as undetectable HCV RNA in serum,24 wk after the end of treatment,was remarkably high by84.4%,(146/173) by an intention-to-treat analysis.Asignificant difference in SVR was found between patientswith and without the discontinuation of ribavirin (46.9%vs 92.9%),but no difference was found between thosewith and without a dose reduction of ribavirin.A signifi-cant difference in SVR was also found between patientswith less than 16 wk and patients with 16 or more weeksof ribavirin treatment (34.8 % vs 92.0 %).CONCLUSION:The 24-wk interferon and ribavirintreatment is highly effective for Japanese patientswith HCV genotype 2.The significant predictor of SVRis continuation of the ribavirin treatment for up to 16weeks.
AIM: To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese pa-tients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. METHODS: In total, 173 patients with HCV genotype 2 start The entire sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. Another difference was found in patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between thosewith and without a dose reduction of ribavirin. A signifi-cant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). CONCLUSION: The 24-wk interferon and ribavirin treatment i s highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVRis continuation of the ribavirin treatment for up to 16 weeks.